Financial comparisons Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.890 USD | -0.25% |
|
-11.45% | -10.54% |
| 03-05 | Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target | MT |
| 03-05 | Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 216M | -102.02% | -69.95% | - | - | - | |
| 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 606M | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 3.69B | 25.89% | 28.63% | 20.56% | 12.29% | -1.54x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 2.32B | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 958M | -30.08% | -31.31% | -42.49% | - | 2.15x | |
| 113M | -310.18% | -226% | - | - | - | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 498M | 32.27% | 31.52% | 16.33% | 13.74% | -4x | |
| 88.04M | -891.6% | -695.44% | - | -54.35% | 0.77x | |
| Average | 1.53B | -95.73% | -76.4% | -17.57% | 0.48% | 64.07x | |
| Weighted average by Cap. | 2.24B | -51.83% | -49.16% | -26.97% | 3.63% | 148.84x |
- Stock Market
- Equities
- VNDA Stock
- Sector Vanda Pharmaceuticals Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition